Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I safety study of oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
Authors
Boris Minev
Calidi Biotherapeutics, San Diego, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Vaccines and Oncolytic Viruses
Clinical Trial Registration Number
ISRCTN#10201650
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 39)
DOI
10.1200/JCO.2019.37.8_suppl.39
Abstract #
39
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas.
First Author: Marka Crittenden
Poster
2013 ASCO Annual Meeting
Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.
First Author: Neil Lorne Berinstein
First Author: Joseph W. Kim
Poster
2023 ASCO Annual Meeting
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
First Author: Yang Zhang